PHARMAC and tobacco control in New Zealand: two licensed funded options are already available.
Scott
S
Metcalfe
Peter
P
Moodie
Wayne
W
McNee
D000279:Administration, Cutaneous; D016642:Bupropion / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D004345:Drug Industry; D019317:Evidence-Based Medicine; D006801:Humans; D008004:Licensure; D009520:New Zealand; D009538:Nicotine / Q000008:administration & dosage; D009661:Nortriptyline / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic / Q000592:standards*; D016540:Smoking Cessation / Q000191:economics / Q000331:legislation & jurisprudence / Q000379:methods*; D014029:Tobacco Use Disorder / Q000517:prevention & control*; D014481:United States
D016642:Bupropion; D009538:Nicotine; D009661:Nortriptyline